Alira Health

We Announce our role as Strategic Advisor to Mérieux Equity Partners and Mérieux Participations 3 for Entering the Capital of CTRS

News
Category:
Published on:
December 20, 2020

Alira Health is pleased to announce its role as strategic advisor to Mérieux Equity Partners as they join the Series A financing round of Cell-Easy, through Mérieux’s newly established venture fund, OMX.

Merieux Equity Partners is a global asset manager specialized in the healthcare and nutrition sectors. Cell-Easy is a novel French pharmaceutical laboratory specialized in the development and manufacturing of novel cell therapies for preclinical and clinical studies. This fund raising aims at accelerating the company’s growth in France and internationally, by expanding the Cell-Easy Management Team and strengthening the company’s commercial presence in key regions.

To read the press release on BusinessWire, click here.

For more information, contact Joris Pezzini.

For more information about Alira Health Transaction Advisory services

Click here

Aenean ut neque vehicula, iaculis odio ut, porta risus. In gravida libero faucibus ex vulputate pharetra. Donec sed sapien odio. Donec vel pellentesque eros. Aliquam erat volutpat. Suspendisse luctus massa accumsan, egestas lacus ac, aliquam libero. Praesent mollis magna vel mi fermentum pulvinar. Fusce quis ultricies sapien, eu suscipit ligula. Duis ut enim ac felis scelerisque sodales. Quisque a elit ac mi cursus posuere vitae sed augue. Nunc varius a ex eget posuere. Nullam fringilla aliquet diam. Maecenas mattis ac massa id fermentum. Proin convallis dui sit amet urna volutpat, ac rutrum magna volutpat. Sed gravida tincidunt laoreet. Nulla nec enim vitae nulla vehicula tempus.

Related news

Case Studies March 20, 2025
Pharma Company Defines Advocacy Strategy Through Data-Driven Patient Association Mapping
Alira Health mapped 253 CVRM patient advocacy groups across 11 countries, delivering a data-driven strategy to optimize partnerships, advocacy efforts, and differentiation.
Patient Advocacy Patient Engagement Pharma
Case Studies March 6, 2025
Rare Disease Pharma Maps Rare Cholestatic Liver Disease Journey for Targeted Patient Engagement
A global pharmaceutical company specializing in rare diseases, oncology, and neuroscience sought to analyze the patient journey for progressive familial intrahepatic cholestasis (PFIC).
Patient Centricity Pharma Rare Disease
Articles February 17, 2025
Rethinking Rare Disease Development: An Integrated, Patient Access-Driven Approach
Explore how biotech companies can succeed in rare disease by integrating development, commercialization, and patient access.
Patient Centricity Pharma Rare Disease
Articles February 11, 2025
From Diagnosis to Long-Term Care: Navigating the Rare Disease Journey
For Rare Disease Day, we spoke with patient engagement expert Luca Trentin on challenges faced by rare disease patients and how pharma can better understand their needs.
Patient Centricity Pharma Rare Disease
News January 8, 2025
Alira Health Launches the Global Payer Forum 2025 in Partnership with UPF Barcelona School of Management, NEWDIGS at Tufts Medical Center, and the University College of London
Alira Health is excited to announce the second year of the Global Payer Forum, a landmark educational initiative in partnership with distinguished academic institutions, UPF Barcelona(...)
Health Policy Market Access Pharma
Articles December 10, 2024
2024 Antibody-Drug Conjugates Landscape: Market Expansion, Innovations, and Strategic Acquisitions
Antibody-Drug Conjugates (ADCs) have emerged as a groundbreaking strategy in precision oncology, uniquely merging the specificity of antibodies with the potency of cytotoxic drugs.
ADC Antibody-Drug Conjugates Pharma
News December 2, 2024
Alira Health Unveils 2024 Report on Antibody-Drug Conjugates Market
This in-depth report explores emerging trends, competitive dynamics, market opportunities, cutting-edge innovations, and pivotal transactions shaping the antibody-drug conjugates (ADC) market.
ADC Antibody-Drug Conjugates Pharma
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.